NEO PE Ratio & Valuation, Is NEO Overvalued

Historical Valuation

Neogenomics Inc (NEO) is now in the Fair zone, suggesting that its current forward PS ratio of 1.96 is considered Fairly compared with the five-year average of 6.69. The fair price of Neogenomics Inc (NEO) is between 4.77 to 25.52 according to relative valuation method.

Relative Value

Fair Zone

4.77-25.52

Current Price：8.56

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Neogenomics Inc (NEO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Neogenomics Inc (NEO) has a current Price-to-Book (P/B) ratio of 1.81. Compared to its 3-year average P/B ratio of 1.87, the current P/B ratio is approximately -3.15% higher. Relative to its 5-year average P/B ratio of 2.36, the current P/B ratio is about -23.39% higher. Neogenomics Inc (NEO) has a Forward Free Cash Flow (FCF) yield of approximately -1.12%. Compared to its 3-year average FCF yield of -2.30%, the current FCF yield is approximately -51.32% lower. Relative to its 5-year average FCF yield of -3.51%, the current FCF yield is about -68.07% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NEO competitors is 1.19, providing a benchmark for relative valuation. Neogenomics Inc Corp (NEO.O) exhibits a P/S ratio of 1.96, which is 64.16% above the industry average. Given its robust revenue growth of 10.56%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NEO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NEO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NEO currently overvalued or undervalued?

What is Neogenomics Inc (NEO) fair value?

NEO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Neogenomics Inc (NEO) is between 4.77 to 25.52 according to relative valuation method.

How does NEO's valuation metrics compare to the industry average?

The average P/S ratio for NEO's competitors is 1.19, providing a benchmark for relative valuation. Neogenomics Inc Corp (NEO) exhibits a P/S ratio of 1.96, which is 64.16% above the industry average. Given its robust revenue growth of 10.56%, this premium appears unsustainable.

What is the current P/B ratio for Neogenomics Inc (NEO) as of Mar 12 2026?

As of Mar 12 2026, Neogenomics Inc (NEO) has a P/B ratio of 1.81. This indicates that the market values NEO at 1.81 times its book value.

What is the current FCF Yield for Neogenomics Inc (NEO) as of Mar 12 2026?

As of Mar 12 2026, Neogenomics Inc (NEO) has a FCF Yield of -1.12%. This means that for every dollar of Neogenomics Inc's market capitalization, the company generates -1.12 cents in free cash flow.

What is the current Forward P/E ratio for Neogenomics Inc (NEO) as of Mar 12 2026?

As of Mar 12 2026, Neogenomics Inc (NEO) has a Forward P/E ratio of 79.57. This means the market is willing to pay $79.57 for every dollar of Neogenomics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Neogenomics Inc (NEO) as of Mar 12 2026?

As of Mar 12 2026, Neogenomics Inc (NEO) has a Forward P/S ratio of 1.96. This means the market is valuing NEO at $1.96 for every dollar of expected revenue over the next 12 months.

NEO Valuation